Purchase by Waksal Harlan of 25000 shares of Lyra TherapeuticsInc
LYRA Stock | USD 0.19 0.01 5.56% |
About 71 percent of all Lyra Therapeutics' investors are curious in acquiring. The analysis of the overall investor sentiment regarding Lyra Therapeutics suggests that a large number of traders are confidant. The current market sentiment, together with Lyra Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Lyra Therapeutics stock news signals to limit their universe of possible portfolio assets.
Lyra |
Filed transaction by Lyra Therapeutics Inc director. General open market or private purchase of non-derivative or derivative security
Read at macroaxis.com
Cash Flow Correlation
Lyra Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Lyra Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Lyra Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Lyra Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Lyra Therapeutics Fundamental Analysis
We analyze Lyra Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lyra Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lyra Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Outstanding
Shares Outstanding Comparative Analysis
Lyra Therapeutics is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Lyra Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Lyra Therapeutics stock to make a market-neutral strategy. Peer analysis of Lyra Therapeutics could also be used in its relative valuation, which is a method of valuing Lyra Therapeutics by comparing valuation metrics with similar companies.
Peers
Lyra Therapeutics Related Equities
CTMX | CytomX Therapeutics | 7.87 | ||||
BOLT | Bolt Biotherapeutics | 3.45 | ||||
NUVB | Nuvation Bio | 3.21 | ||||
CGEM | Cullinan Oncology | 2.62 | ||||
AUTL | Autolus Therapeutics | 1.36 | ||||
ACHL | Achilles Therapeutics | 0.94 | ||||
NXTC | NextCure | 0.84 | ||||
TIL | Instil Bio | 0.08 | ||||
SPRO | Spero Therapeutics | 0.86 | ||||
ASMB | Assembly Biosciences | 1.53 | ||||
DAWN | Day One | 2.19 |
Complementary Tools for Lyra Stock analysis
When running Lyra Therapeutics' price analysis, check to measure Lyra Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lyra Therapeutics is operating at the current time. Most of Lyra Therapeutics' value examination focuses on studying past and present price action to predict the probability of Lyra Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lyra Therapeutics' price. Additionally, you may evaluate how the addition of Lyra Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
CEOs Directory Screen CEOs from public companies around the world |